Cathepsin L (EC 3.4.22.15) - Pipeline Review, H1 2016

  • ID: 3775390
  • Report
  • 30 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • OXiGENE, Inc.
  • Phelix Therapeutics, LLC
  • Virobay Inc.
  • MORE
Cathepsin L (EC 3.4.22.15) - Pipeline Review, H1 2016

Summary

‘Cathepsin L (EC 3.4.22.15) - Pipeline Review, H1 2016’, provides in depth analysis on Cathepsin L (EC 3.4.22.15) targeted pipeline therapeutics.

The report provides comprehensive information on the Cathepsin L (EC 3.4.22.15), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin L (EC 3.4.22.15) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cathepsin L (EC 3.4.22.15)
- The report reviews Cathepsin L (EC 3.4.22.15) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cathepsin L (EC 3.4.22.15) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cathepsin L (EC 3.4.22.15) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cathepsin L (EC 3.4.22.15) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cathepsin L (EC 3.4.22.15)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cathepsin L (EC 3.4.22.15) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • OXiGENE, Inc.
  • Phelix Therapeutics, LLC
  • Virobay Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Cathepsin L (EC 3.4.22.15) Overview

Therapeutics Development

Cathepsin L (EC 3.4.22.15) - Products under Development by Stage of Development

Cathepsin L (EC 3.4.22.15) - Products under Development by Therapy Area

Cathepsin L (EC 3.4.22.15) - Products under Development by Indication

Cathepsin L (EC 3.4.22.15) - Pipeline Products Glance

Early Stage Products

Cathepsin L (EC 3.4.22.15) - Products under Development by Companies

Cathepsin L (EC 3.4.22.15) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cathepsin L (EC 3.4.22.15) - Companies Involved in Therapeutics Development

OXiGENE, Inc.

Phelix Therapeutics, LLC

Virobay Inc.

Cathepsin L (EC 3.4.22.15) - Drug Profiles

Drugs to Inhibit Cathepsin L for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KGP-94 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBY-129 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBY-285 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBY-825 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBY-X - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cathepsin L (EC 3.4.22.15) - Dormant Projects

Cathepsin L (EC 3.4.22.15) - Featured News & Press Releases

Apr 07, 2014: OXiGENE Announces Results of KGP94 Preclinical Studies at 2014 AACR Conference

Mar 27, 2014: OXiGENE Announces Presentation of Preclinical Abstracts at 2014 AACR Conference

Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by OXiGENE, Inc., H1 2016

Pipeline by Phelix Therapeutics, LLC, H1 2016

Pipeline by Virobay Inc., H1 2016

Dormant Projects, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • OXiGENE, Inc.
  • Phelix Therapeutics, LLC
  • Virobay Inc.
  • MORE
Cathepsin L (EC 3.4.22.15) Cathepsin L, a lysosomal endopeptidase is a member of the papain-like family of cysteine proteinases. Cathepsin L plays a major role in antigen processing, tumor invasion and metastasis, bone resorption, and turnover of intracellular and secreted proteins involved in growth regulation. Although commonly recognized as a lysosomal protease, cathepsin L is also secreted. The cathepsin L gene is activated by a variety of growth factors, tumor promoters, and second messengers. Cathepsin L promote tumor cell invasion and metastasis by catalyzing degradation of the interstitial matrix and basement membranes, thus allowing cancer cells to invade locally and metastasize to distant sites.

Cathepsin L (EC 3.4.22.15) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies.The molecules developed by Companies in Phase I, Phase 0, Preclinical and Discovery stages are 1, 1, 3 and 1 respectively.

Our latest report Cathepsin L (EC 3.4.22.15) – Pipeline Review, H1 2016, outlays comprehensive information on the Cathepsin L (EC 3.4.22.15) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cathepsin L (EC 3.4.22.15) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
OXiGENE, Inc.
Phelix Therapeutics, LLC
Virobay Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll